drugset / Trial / NCT00857532
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
Phase 2
Completed
31 enrolled
Avid Radiopharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS) · collabNational Institutes of Health (NIH) · collab
Non-randomizedSingle-groupSingle-blindDiagnostic
Summary
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
Timeline
- Start
- 2009-01
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | florbetapir F 18 | Diagnostic / imaging agent | 370 mbq | — |